DPP-4s’ Prime Advantage Is Pancreatic Safety Profile, Bristol Says
Executive Summary
The ability to preserve pancreatic function is the primary competitive advantage for DPP-4 inhibitors relative to sulfonylureas, according to Bristol-Myers Squibb Senior VP-Global Clinical Development Brian Daniels. Bristol is initially developing DPP-4 inhibitors for diabetes
You may also be interested in...
Galvus “Approvable”: Additional Trial To Be Relatively Small, Short – Novartis
FDA will likely require Novartis to conduct a clinical trial of the dipeptidyl peptidase-4 inhibitor Galvus in a relatively small number of patients that are predisposed to achieving high plasma levels with standard doses of the drug, Novartis Global Pharma Development Head James Shannon said
Bristol/Astra Diabetes Deal Further Indicates Bristol Will Stay Independent
Bristol-Myers Squibb's partnership with AstraZeneca for two of its top diabetes candidates may diminish chances that Bristol will be merged
Hologic's Adiana Permanent Birth Control Device Takes On Conceptus' Essure
Adiana uses a polymer matrix insert to block the fallopian tubes instead of a metal coil, offering a benefit over Essure, which carries a perforation risk on implantation, Hologic exec says.